Canakinumab Anti-inflammatory Thrombosis Outcomes Study
GPTKB entity
Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:abbreviation |
gptkb:CANTOS
|
| gptkbp:clinicalTrials.govIdentifier |
gptkb:NCT01327846
|
| gptkbp:controls |
placebo
|
| gptkbp:enrollment |
over 10,000 patients
|
| gptkbp:foundIn |
canakinumab reduced recurrent cardiovascular events
canakinumab increased risk of fatal infection canakinumab reduced inflammation (CRP levels) |
| https://www.w3.org/2000/01/rdf-schema#label |
Canakinumab Anti-inflammatory Thrombosis Outcomes Study
|
| gptkbp:intervention |
canakinumab 150 mg
canakinumab 300 mg canakinumab 50 mg |
| gptkbp:location |
international
|
| gptkbp:population |
patients with prior myocardial infarction
|
| gptkbp:publicationYear |
2017
|
| gptkbp:publishedIn |
gptkb:New_England_Journal_of_Medicine
|
| gptkbp:result |
cardiovascular event reduction
|
| gptkbp:sponsor |
gptkb:Novartis
|
| gptkbp:startYear |
2011
|
| gptkbp:studiedDrug |
gptkb:canakinumab
|
| gptkbp:studyType |
gptkb:clinical_trial
|
| gptkbp:bfsParent |
gptkb:CANTOS_trial
|
| gptkbp:bfsLayer |
6
|